Profil
Dr. Mark L.
Levitt is a Chief Scientific Officer at RedHill Biopharma Ltd. He is on the Board of Directors at EnGeneIC Pty Ltd. Dr. Levitt was previously employed as a Head-Lung Cancer Unit by Sheba Medical Center.
He also served on the board at UPMC Cancer Institute.
Postes actifs de Mark L. Levitt
| Sociétés | Poste | Début |
|---|---|---|
| REDHILL BIOPHARMA LTD. | Directeur Technique/Scientifique/R&D | 01/01/2022 |
EnGeneIC Pty Ltd.
EnGeneIC Pty Ltd. BiotechnologyHealth Technology Develops and commercializes novel concepts for the targeted delivery of drugs and other therapeutic molecules used in the treatment of cancer | Directeur/Membre du Conseil | - |
Anciens postes connus de Mark L. Levitt
| Sociétés | Poste | Fin |
|---|---|---|
UPMC Cancer Institute
UPMC Cancer Institute Medical/Nursing ServicesHealth Services Provides health care and insurance services | Directeur/Membre du Conseil | - |
Sheba Medical Center
Sheba Medical Center Hospital/Nursing ManagementHealth Services Operates as a hospital | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
EnGeneIC Pty Ltd.
EnGeneIC Pty Ltd. BiotechnologyHealth Technology Develops and commercializes novel concepts for the targeted delivery of drugs and other therapeutic molecules used in the treatment of cancer | Health Technology |
Sheba Medical Center
Sheba Medical Center Hospital/Nursing ManagementHealth Services Operates as a hospital | Health Services |
UPMC Cancer Institute
UPMC Cancer Institute Medical/Nursing ServicesHealth Services Provides health care and insurance services | Health Services |
RedHill Biopharma Ltd.
RedHill Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provides GI, infectious diseases, medical countermeasures and oncology services | Health Technology |
















